Eximore ⚠ Under review

Under review — some data on this profile may be inaccurate and is being re-verified.

Revolutionizing the delivery and efficacy of eye medication to reduce risk and improve patient outcomes for ophthalmic conditions.

Health Tech & Life Sciences
Active
Series A Tel Aviv, Israel Founded 2014
Website ↗
Last updated 2026-07-20
Total raised
$3.6M
Last: Undisclosed Round 2018-05
Stage
Series A
Founded
2014
Headcount
7
HQ
Tel Aviv, Israel
Sector
Health Tech & Life Sciences

About

Eximore is a biopharmaceutical platform company focused on designing innovative solutions for the ophthalmological community. The company has developed a non-invasive patented punctal plug drug delivery system that uses nano-particle technology to mold active drug into the plug itself, providing sustained release of medication. This integrated “Pack & Release” delivery system aims to increase patient compliance, optimize consistent dosing, and improve patient outcomes for chronic conditions such as glaucoma and dry eye syndrome.

Funding history · 2 rounds · $3.6M total

2018-04
A Round $3.0M
★ VLX Ventures★ Rimonci Capital★ Docor International Management
2013-11
Seed $600K
★ VLX Ventures★ Xenia Venture Capital

Headcount over time

From 3 (2015-06) to 8 (2023-05) · +5 (+167%) · 4 points · source: Finder history + radar grounding
80 2015-06 2023-05

Q&A

What is Eximore's primary focus?
Eximore is developing ophthalmic drug-delivery products, specifically a noninvasive punctal plug designed to release glaucoma drugs over a long period to improve patient compliance.
Where is Eximore headquartered?
Eximore is headquartered in Shoham, Israel.
When was Eximore founded?
Eximore was founded in November 2013.
What is Eximore's current employee count?
Eximore has 3 employees, falling within the 1-10 employee bucket.
What is Eximore's total funding raised to date?
Eximore has raised a total of $3,600,000 USD.
When was Eximore's most recent funding round and who were the investors?
Eximore's most recent funding round occurred in May 2018, with investments from VLX Ventures and Rimonci Capital.
What is Eximore's primary sector classification?
Eximore's primary sector is Health Tech & Life Sciences.

Team · 2

Eyal Sheetrit
Founder · Co-Founder & CEO
Guy Ben Simon
Founder · Co-Founder

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug DeliveryMedical DevicesMedical Treatment & Therapeutics
Technologies
Materials & Substances
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2CB2B

Highlights

1 PatentsVerified

Tags

bioconvergencepersonalizationnon-invasiveeye-diseasesmedical-technologiesdrug-deliveryophthalmologyglaucomamedical-devicesadherenceclinicsbiopharmaceutical
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)

External links

Websiteeximore.co.il/

Identifiers & details

Legal nameEximore Ltd
Founded2014
Employees (exact)7

Radar intelligence

Patents

EPO5

Web history (Wayback)

Domaineximore.co.il

Certificate / subdomain footprint

Subdomains2

Israeli Companies Registrar (רשם החברות / ICA)

Registrar # (ח.פ.)514996487
Statusפעילה
Corp typeישראלית חברה פרטית
Incorporated2013-11-28
Purposeלעסוק בכל עיסוק חוקי
Liabilityמוגבלת
In violation (unfiled)yes
Last annual report2022
Active charges / liens0
Registry events1 — other (1)
Registered addressקפלן 0 ירושלים

Recent registry events

DateEvent
2025-12-15עדכון חיובים במג~ק